Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro

International Journal of Clinical Oncology

Volumn 19, Issue 3, 2014, Pages 497-504

  Fukui, Naotaka ^a   Kageyama, Yukio ^a   Higashi, Yotsuo ^a   Kihara, Kazunori ^b   Kizaka Kondoh, Shinae ^c   Hiraoka, Masahiro ^d   Shinojima, Toshiaki ^e   Suzuki, Kenjiro ^e   Oya, Mototsugu ^e  

^a SAITAMA CANCER CENTER   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Hypoxia inducible factor; Interferon; Renal cell carcinoma; von Hippel Lindau protein

Indexed keywords

ALBINTERFERON ALPHA2B; DEFEROXAMINE MESYLATE; HYPOXIA INDUCIBLE FACTOR; VON HIPPEL LINDAU PROTEIN; ALPHA INTERFERON; ALPHA2B INTERFERON; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CULTURE MEDIUM; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT PROTEIN; VHL PROTEIN, HUMAN;

ADVANCED CANCER; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING SITE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MTS ASSAY; PRIORITY JOURNAL; RENAL CELL CARCINOMA CELL LINE; TREATMENT RESPONSE; BINDING SITE; CARCINOMA, RENAL CELL; CELL SURVIVAL; CULTURE MEDIUM; DNA RESPONSIVE ELEMENT; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; PHARMACOLOGY; PROCEDURES; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; GENETIC THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERFERON-ALPHA; KIDNEY NEOPLASMS; RECOMBINANT PROTEINS; RESPONSE ELEMENTS; TRANSFECTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84903314813     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0568-z     Document Type: Article

References (33)

1. McLaughlin JK, Lipworth L (2000) Epidemiologic aspects of renal cell cancer. Semin Oncol 27:115-123 (Pubitemid 30205367)
2. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865-875
3. Board RE, Thistlethwaite FC, Hawkins RE (2007) Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 33:1-8 (Pubitemid 46132000)
4. Patel NP, Lavengood RW (1978) Renal cell carcinoma: natural history and results of treatment. J Urol 119:722-726 (Pubitemid 8369927)
5. Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. J Urol 163:408-417
6. MRC (1999) Interferon-alpha and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353:14
7. Patard JJ, Pignot G, Escudier B et al (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol 60:684-690
8. Nickerson ML, Jaeger E, Shi Y et al (2008) Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 14:4726-4734
9. Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59:5830-5835
10. Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421 (Pubitemid 30626905)
11. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207-214
12. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634
13. Lidgren A, Hedberg Y, Grankvist K et al (2005) The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11:1129-1135 (Pubitemid 40175762)
14. Klatte T, Seligson DB, Riggs SB et al (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13:7388-7393
15. Greco O, Patterson AV, Dachs GU (2000) Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res 41:201-212
16. Harada H, Kizaka-Kondoh S, Itasaka S et al (2007) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360:791-796 (Pubitemid 47077390)
17. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal-cell carcinoma. N Engl J Med 345:1655-1659 (Pubitemid 33126820)
18. Pyrhonen S, Salminen E, Ruutu M et al (1999) Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859-2867 (Pubitemid 29415245)
19. Shinojima T, Oya M, Takayanagi A et al (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 28:529-536 (Pubitemid 46523348)
20. Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4:182-193 (Pubitemid 43143791)
21. Huang LE, Gu J, Schau M et al (1998) Regulation of hypoxiainducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992
22. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340 (Pubitemid 33063099)
23. Jaakkola P, Mole DR, Tian YM et al (2001) Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472 (Pubitemid 32335942)
24. Kivirikko KI, Pihlajaniemi T (1998) Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 72:325-398
25. Yuan F, Chen Y, Dellian M et al (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770 (Pubitemid 26419043)
26. Hon WC, Wilson MI, Harlos K et al (2002) Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417:975-978 (Pubitemid 34716877)
27. Min JH, Yang H, Tian M et al (2002) Structure of an HIF-1αpVHL complex: hydroxyproline recognition in signaling. Science 296:1886-1889 (Pubitemid 34596278)
28. Semenza GL (2010) Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2:336-361
29. Mandriota SJ, Turner KJ, Davies DR et al (2002) HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468 (Pubitemid 41039126)
30. Gordan JD, Lal P, Dondeti VR et al (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14:435-446
31. Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev Jan 25;(1):CD001425
32. Bracarda S, Porta C, Boni C et al (2013) Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol 63:254-261
33. Canil C, Hotte S, Mayhew LA et al (2010) Interferon-alpha in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J 4:201-208